Skip to content
2000
Volume 21, Issue 4
  • ISSN: 1573-3947
  • E-ISSN: 1875-6301

Abstract

Introduction

Breast cancer is recognized as the most prevalent form of cancer in women. The aim of the present study was to examine tumor-related biomarkers such as ER, PR, HER2/neu, P53, Ki-67, CEA, CA-125, and CA 15-3 in women with breast cancer referred to Naft Hospital of Ahvaz, southwest Iran.

Methods

This research was a cross-sectional investigation. A total of 100 Iranian women patients were selected who were diagnosed with breast cancer tumors (stage 3). All tumor markers like CEA, CA 15-3, and CA-125 were determined using a chemiluminescent instrument. In addition, the immunohistochemical technique was used to analyze the expression of ER, PR, HER/neu, Ki-67 antigen, and P53 protein.

Results

The mean of patients' age was 48.53 ± 9.57 years. ER accounted for the highest frequency (73, or 73%) out of 100 cases. There were 69 (69%), 55 (55%), and 53 (53%) positive cases for PR, HER2/neu, and P53, respectively. The chi-square analysis revealed a significant difference for HER2/neu and P53 biomarkers ( = 0.027). The odds ratio was 2.625 [95% CI: (1.167-5.906)], and the positive correlation between them was 0.236 ( = 0.018). Moreover, a significant difference was found for ER and PR biomarkers ( < 0.0001), and the odds ratio was 18.25 [95% CI: (7.039-47.319)]. There was a significant positive correlation ( = 0.908, < 0.0001) between ER and PR. A remarkable positive correlation (r = 0.256, = 0.010) was also observed between CEA and CA 15-3 biomarkers.

Conclusion

Our findings indicated that the highest frequency of tumor-associated biomarkers was ER, and there was a positive correlation between ER and PR, HER2/neu, and P53, as well as CEA and CA 15-3.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cctr/10.2174/0115733947293619240521120939
2024-05-28
2025-09-02

  • From This Site

    /content/journals/cctr/10.2174/0115733947293619240521120939
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sadegh-NejadiS. AfrishamR. EmamgholipourS. Influence of plasma circulating exosomes obtained from obese women on tumorigenesis and tamoxifen resistance in MCF ‐7 cells.IUBMB Life20207291930194010.1002/iub.2305 32542981
     [Google Scholar]
  2. OnitiloA.A. EngelJ.M. GreenleeR.T. MukeshB.N. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.Clin. Med. Res.200971-241310.3121/cmr.2008.825 19574486
     [Google Scholar]
  3. AhnS.G. YoonC.I. LeeJ.H. Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation and high SUV.Endocr. Relat. Cancer201926217718510.1530/ERC‑18‑0281 30407916
     [Google Scholar]
  4. KhandeparkarS.G.S. KhandeT.A. JoshiA.R. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.Indian J. Cancer202057219019710.4103/ijc.IJC_610_18 32445323
     [Google Scholar]
  5. UrruticoecheaA. SmithI.E. DowsettM. Proliferation marker Ki-67 in early breast cancer.J. Clin. Oncol.200523287212722010.1200/JCO.2005.07.501 16192605
     [Google Scholar]
  6. ArunB. KilicG. YenC. Correlation of bcl‐2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes.Cancer200398122554255910.1002/cncr.11853 14669273
     [Google Scholar]
  7. FangC. CaoY. LiuX. ZengX.T. LiY. Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes.Oncotarget2017838639636397010.18632/oncotarget.19246 28969044
     [Google Scholar]
  8. ShaoY. SunX. HeY. LiuC. LiuH. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer.PLoS One2015107e013383010.1371/journal.pone.0133830 26207909
     [Google Scholar]
  9. TarighatiE. KeivanH. MahaniH. A review of prognostic and predictive biomarkers in breast cancer.Clin. Exp. Med.202323111610.1007/s10238‑021‑00781‑1 35031885
     [Google Scholar]
  10. WuS. HeZ. ZhouJ. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer.Breast2014231889310.1016/j.breast.2013.11.003 24291374
     [Google Scholar]
  11. DuffyM.J. EvoyD. McDermottE.W. CA 15-3: Uses and limitation as a biomarker for breast cancer.Clin. Chim. Acta201041123-241869187410.1016/j.cca.2010.08.039 20816948
     [Google Scholar]
  12. LiJ. LiuL. FengZ. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study.Breast Cancer202027462163010.1007/s12282‑020‑01058‑3 32040723
     [Google Scholar]
  13. ZwartW. TheodorouV. CarrollJ.S. Estrogen receptor‐positive breast cancer: a multidisciplinary challenge.Wiley Interdiscip. Rev. Syst. Biol. Med.20113221623010.1002/wsbm.109 21305704
     [Google Scholar]
  14. KumarR. ZakharovM.N. KhanS.H. MikiR. JangH. ToraldoG. The dynamic structure of the estrogen receptor.J. Amino Acids2011201181254010.4061/2011/812540
     [Google Scholar]
  15. WeigelM.T. DowsettM. Current and emerging biomarkers in breast cancer: prognosis and prediction.Endocr. Relat. Cancer2010174R245R26210.1677/ERC‑10‑0136 20647302
     [Google Scholar]
  16. LumachiF. BrunelloA. MaruzzoM. BassoU. BassoS. Treatment of estrogen receptor-positive breast cancer.Curr. Med. Chem.201320559660410.2174/092986713804999303 23278394
     [Google Scholar]
  17. KabelA.M. ElkhoelyA.A. Ameliorative potential of fluoxetine/raloxifene combination on experimentally induced breast cancer.Tissue Cell2016482899510.1016/j.tice.2016.02.002 26881735
     [Google Scholar]
  18. HanH.H. LeeS.H. KimB.G. LeeJ.H. KangS. ChoN.H. Estrogen receptor status predicts late-onset skeletal recurrence in breast cancer patients.Medicine2016958e290910.1097/MD.0000000000002909 26937933
     [Google Scholar]
  19. BeijeN. OnstenkW. KraanJ. Prognostic impact of HER2 and ER status of circulating tumor cells in metastatic breast cancer patients with a HER2-negative primary tumor.Neoplasia2016181164765310.1016/j.neo.2016.08.007 27764697
     [Google Scholar]
  20. BaeS.Y. KimS. LeeJ.H. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.BMC Cancer201515113810.1186/s12885‑015‑1121‑4 25880075
     [Google Scholar]
  21. CaoW. ZhangB. LiuY. High-level SLP-2 expression and HER-2/neu protein expression are associated with decreased breast cancer patient survival.Am. J. Clin. Pathol.2007128343043610.1309/C6X54HRB580EP2NQ 17709317
     [Google Scholar]
  22. ReixN. MalinaC. ChenardM.P. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.Breast Cancer Res. Treat.2016160224925910.1007/s10549‑016‑4000‑z 27709352
     [Google Scholar]
  23. MolinaR. BarakV. van DalenA. Tumor markers in breast cancer- european group on tumor markers recommendations.Tumour Biol.200526628129310.1159/000089260 16254457
     [Google Scholar]
  24. LiJ. GuanX. FanZ. Non-invasive biomarkers for early detection of breast cancer.Cancers20201210276710.3390/cancers12102767 32992445
     [Google Scholar]
  25. Opstal-van WindenA. RodenburgW. PenningsJ.L.A. A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum.Int. J. Mol. Sci.20121312135871360410.3390/ijms131013587 23202969
     [Google Scholar]
  26. YangJ. QiuL. WangX. Liquid biopsy biomarkers to guide immunotherapy in breast cancer.Front. Immunol.202314130349110.3389/fimmu.2023.1303491 38077355
     [Google Scholar]
  27. HesariA. Golrokh MoghadamS.A. SiasiA. Tumor‐derived exosomes: Potential biomarker or therapeutic target in breast cancer?J. Cell. Biochem.201811964236424010.1002/jcb.26364 28833502
     [Google Scholar]
  28. GasparriM.L. CasorelliA. BardhiE. Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer.Tumour Biol.2017395101042831769552510.1177/1010428317695525 28459207
     [Google Scholar]
  29. BeretovJ. WasingerV.C. GrahamP.H. MillarE.K. KearsleyJ.H. LiY. Proteomics for breast cancer urine biomarkers.Adv. Clin. Chem.20146312316710.1016/B978‑0‑12‑800094‑6.00004‑2 24783353
     [Google Scholar]
/content/journals/cctr/10.2174/0115733947293619240521120939
Loading
Examination of Tumor-related Biomarkers in Women with Breast Cancer Referred to Naft Hospital of Ahvaz, Southwest Iran
Curr Cancer Ther Rev 21, 568 (2025); https://doi.org/10.2174/0115733947293619240521120939
/content/journals/cctr/10.2174/0115733947293619240521120939
/content/journals/cctr/10.2174/0115733947293619240521120939
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): CA 15-3 breast cancer; CA-125; cancer in women; estrogen receptor; HER/neu; Ki-67; P53; progesterone receptor

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test